Medivir out-licenses hep C drug to China’s Ascletis; Cellectis launches pioneering UCART123 US study
⇨ Ascletis has in-licensed the Chinese market rights for Stockholm-based Medivir’s NS5B inhibitor for hep C. Terms weren’t disclosed but Hangzhou-based Ascletis gets another piece of the puzzle for a cocktail that can cure hep C, which it plans to hustle to regulators.
⇨ Cellectis $CLLS says they’ve dosed the first patient in their pioneering US human study of the first off-the-shelf CAR-T targeting CD123. The study of UCART123 is being carried out by investigators at MD Anderson in Houston.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.